Invitation to Cosmo’s Investor Day and Full-Year 2023 Webcast – Zurich, 20 March 2024
Dublin, Ireland–(Newsfile Corp. – January 25, 2024) – Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) announced today that it will publish its Full-Year 2023 results on Wednesday, 20 March 2024 at 7:00 am CET.
FY 2023 Results Webcast
Cosmo invites investors, financial analysts and business/life sciences journalists to a live video webcast presentation which will follow at 11:00 am CET with Mauro Ajani, Chairman, and Alessandro Della Chà, CEO, to discuss the financial and operating results as well as perspectives of the Company.
Live conference call and video webcast presentation:
Date: Wednesday, 20 March 2024
Time: 11:00 am CET
Participant Link: Live Webcast
Please note that there is a function to type in questions via webcast.
Via phone:
Participants wishing to ask verbal questions via phone may call the following numbers below. To ensure prompt access, please call approximately ten minutes prior to the scheduled start of the call.
| Switzerland / Europe | +41 (0) 58 310 50 00 |
| United Kingdom | +44 (0) 207 107 06 13 |
| United States | +1 (1) 631 570 56 13 |
The Full-Year Report 2023 as well as the corresponding media release will be available for download as of 7:00 am CET on 20 March 2024 at www.cosmopharma.com.
Replay
The webcast, along with the presentation, will be available online shortly after the event and accessible for three months.
Investor Day in Zurich
Cosmo will host an Investor Day in Zurich on the same day at 15:00 pm CET. The hybrid event will be held in English and include presentations from Cosmo’s management discussing the Company’s latest developments, commercial strategy, and key business highlights.
Date: Wednesday, 20 March 2024
Time: 15:00 pm CET
Location: Park Hyatt Hotel, Beethovenstrasse 21, Zurich
RSVP Pre-registration link (to attend in person, deadline by Friday, 8 March 2024)
We kindly ask investors, analysts and media representatives interested in attending to pre-register via the link provided above. We look forward to welcoming attendees to our Investor day.
Please note that there is a function to type in questions via webcast.
Via phone:
Participants wishing to ask verbal questions via phone may call the following numbers below. To ensure prompt access, please call approximately ten minutes prior to the scheduled start of the call.
| Switzerland / Europe | +41 (0) 58 310 50 00 |
| United Kingdom | +44 (0) 207 107 06 13 |
| United States | +1 (1) 631 570 56 13 |
Agenda
15.00 Welcome and introduction
15:10 Company perspectives and strategy
15:40 GI Genius™ and Medtronic collaboration
16:10 Winlevi® and Breezula® updates
16.30 Clinical pipeline update
17.00 Q&A
18.00 Drinks and stand-up flying dinner
Replay
The webcast along with the presentation will be available online shortly after the event and accessible for three months.
About Cosmo
Cosmo is a pharmaceutical company focused on developing and commercializing products to treat selected gastrointestinal disorders, to improve endoscopy quality measures through aiding the detection of colonic lesions and to treat selected dermatological conditions. Cosmo develops and manufactures products which are distributed globally by selected partners including Lialda®/Mezavant®/Mesavancol®, Uceris®/Cortiment®, Aemcolo®/ Relafalk® and Winlevi®. Cosmo has also developed medical devices for endoscopy and has a partnership with Medtronic for the global distribution of GI Genius™ which uses artificial intelligence to help detect potential signs of colon cancer. The company also has a rich development pipeline. For additional information on Cosmo and its products, please visit www.cosmopharma.com.
Contact:
Hazel Winchester
Head of Investor Relations
Cosmo Pharmaceuticals N.V.
Tel: +353 1 817 03 70
Attachments
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/195636
